Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2016

01-01-2016 | Original Article

The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes

Authors: Nabil Amara, Jolyane Blouin-Bougie, Jalila Jbilou, Norrin Halilem, Jacques Simard, Réjean Landry

Published in: Familial Cancer | Issue 1/2016

Login to get access

Abstract

The aim of this paper is twofold: to analyze the genetic counseling process for breast cancer with a theoretical knowledge transfer lens and to compare generalists, medical specialists, and genetic counselors with regards to their genetic counseling practices. This paper presents the genetic counseling process occurring within a chain of value-adding activities of four main stages describing health professionals’ clinical practices: (1) evaluation, (2) investigation, (3) information, and (4) decision. It also presents the results of a cross-sectional study based on a Canadian medical doctors and genetic counselors survey (n = 176) realized between July 2012 and March 2013. The statistical exercise included descriptive statistics, one-way ANOVA and post-hoc tests. The results indicate that even though all types of health professionals are involved in the entire process of genetic counseling for breast cancer, genetic counselors are more involved in the evaluation of breast cancer risk, while medical doctors are more active in the decision toward breast cancer risk management strategies. The results secondly demonstrate the relevance and the key role of genetic counselors in the care provided to women at-risk of familial breast cancer. This paper presents an integrative framework to understand the current process of genetic counseling for breast cancer in Canada, and to shed light on how and where health professionals contribute to the process. It also offers a starting point for assessing clinical practices in genetic counseling in order to establish more clearly where and to what extent efforts should be undertaken to implement future genetic services.
Appendix
Available only for authorised users
Footnotes
1
Abdominal and Breast Surgery; Advanced Gynecological Surgery; Breast Cancer; Breast Disease; Breast Oncology; Breast Pathology; Breast Surgery; Breast Surgical Oncology; Breasts; Cancer Genetics; Cancer Genetics Research; Cancer Medical Gynecology; Cancer/Head, Neck and Breast; Clinical Genetics; Clinical Oncology; Clinical Preventive Medicine; Counselling; Family and Marital Counselling; Gynecological Cancer; Gynecological Oncology; Gynecological Pathology; Gynecological Reproductive Endocrinology; Gynecological Surgery; Gynecology; Gynecology and Infertility; Gynecology Pathology and Cytology; Marital Counselling; Medical Genetics; Medical Oncology; Obstetrics and Gynecology; Oncology Imaging; Oncology/Breast Cancer; Ovarian Disorders; Reproductive Genetics; Reproductive Medicine; Surgical Oncology.
 
2
Breast Cancer; Breast Disease; Clinical Preventive Health; Clinical Preventive Medicine; General Surgery; Gynecological Oncology; Gynecology; Marital and Sexual Counselling; Medical Genetics; Medical Oncology; Obstetrics and Gynecology; Obstetrics and Gynecology; Oncology; Preventive Medicine; Surgical Oncology; Women’s Cancerus; Women’s Issues.
 
Literature
1.
Jolie A (2013) My medical choice: The New York Times. The New York Times Compagnie, New York
2.
Resta R, Biesecker BB, Bennett RL, Blum S, Estabrooks Hahn S, Strecker MN, Williams JL (2006) A new definition of genetic counseling: National society of genetic counselors’ task force report. J Genet Couns 15:77–83PubMedCrossRef
3.
Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S (2004) Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 96:122–133PubMedCrossRef
4.
Lobb EA, Butow PN, Meiser B, Barratt A, Gaff C, Young MA, Kirk J, Suthers GK, Tucker K (2002) Tailoring communication in consultations with women from high risk breast cancer families. Br J Cancer 87:502–508PubMedPubMedCentralCrossRef
5.
Pieterse AH, Van Dulmen AM, Beemer FA, Bensing JM, Ausems MGEM (2007) Cancer genetic counseling: communication and counselees’ post-visit satisfaction, cognitions, anxiety, and needs fulfillment. J Genet Couns 16:85–96PubMedPubMedCentralCrossRef
6.
Smets E, van Zwieten M, Michie S (2007) Comparing genetic counseling with non-genetic health care interactions: Two of a kind? Patient Educ Couns 68:223–225CrossRef
7.
McCann S, MacAuley D, Barnett Y (2005) Genetic consultations in primary care: Gps’ responses to three scenarios. Scand J Prim Health Care 23:109–114PubMedCrossRef
8.
Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CHA, Lishner DM, Goff BA (2011) Reported referral for genetic counseling or brca 1/2 testing among United States physicians: a vignette-based study. Cancer 117:5334–5343PubMedCrossRef
9.
Shields AE, Burke W, Levy DE (2008) Differential use of available genetic tests among primary care physicians in the united states: results of a national survey. Genet Med 10:404–414PubMedPubMedCentralCrossRef
10.
Wham D, Vu T, Chan-Smutko G, Kobelka C, Urbauer D, Heald B (2010) Assessment of clinical practices among cancer genetic counselors. Fam Cancer 9:459–468PubMedCrossRef
11.
Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N (2003) Use of cancer susceptibility testing among primary care physicians. Clin Genet 64:355–360PubMedCrossRef
12.
Burke W, Culver J, Pinsky L, Hall S, Reynolds SE, Yasui Y, Press N (2009) Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A 149A:349–356
13.
Guerra CE, Sherman M, Armstrong K (2009) Diffusion of breast cancer risk assessment in primary care. J Am Board of Family Med JABFM 22:272–279PubMedCrossRef
14.
Haas JS, Kaplan CP, Gregorich SE, Perez-Stable EJ (2004) Des Jarlais G: Do physicians tailor their recommendations for breast cancer risk reduction based on patient’s risk? J Gen Intern Med 19:302–309PubMedPubMedCentralCrossRef
15.
Freedman AN, Wideroff L, Olson L, Davis W, Klabunde C, Srinath KP, Reeve BB, Croyle RT, Ballard-Barbash R (2003) Us physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63–71PubMedCrossRef
16.
Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE (2008) Physicians’ experiences with brca1/2 testing in community settings. J Clin Oncol 26:5789–5796PubMedPubMedCentralCrossRef
17.
Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJT, Ausems MGEM (2010) Brca testing of breast cancer patients: medical specialists’ referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care 19:369–376CrossRef
18.
Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L (2007) The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9:665–674PubMedCrossRef
19.
Han PKJ, Klabunde CN, Breen N, Yuan G, Grauman A, Davis WW, Taplin SH (2011) Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of us primary care physicians. Med Care 49:139–148PubMedPubMedCentralCrossRef
20.
Forrest LE, Delatycki MB, Skene L, Aitken M (2007) Communicating genetic information in families—a review of guidelines and position papers. Eur J Hum Genet 15:612–618PubMedCrossRef
21.
Pieterse AH, Ausems M, Spreeuwenberg P, van Dulmen S (2011) Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. Patient Educ Couns 85:425–431PubMedCrossRef
22.
Howard AF, Balneaves LG, Bottorff JL (2009) Women’s decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. J Genet Couns 18:578–597PubMedCrossRef
23.
Butow PN, Lobb EA (2004) Analyzing the process and content of genetic counseling in familial breast cancer consultations. J Genet Couns 13:403–424PubMedCrossRef
24.
Contegiacomo A, Pensabene M, Capuano I, Tauchmanova L, Federico M, Turchetti D, Cortesi L, Marchetti P, Ricevuto E, Cianci G (2004) An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 15:726–732PubMedCrossRef
25.
26.
Ellington L, Roter D, Dudley WN, Baty BJ, Upchurch R, Larson S, Wylie JE, Smith KR, Botkin JR (2005) Communication analysis of brca1 genetic counseling. J Genet Couns 14:377–386PubMedCrossRef
27.
Bouchard L, Blancquaert I, Eisinger F, Foulkes WD, Evans G, Sobol H, Julian-Reynier C (2004) Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med 58:1085–1096PubMedCrossRef
28.
Cho MK, Sankar P, Wolp PR, Godmilow L (1999) Commercialization of brca1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet 83:157–163PubMedPubMedCentralCrossRef
29.
Jbilou J, Halilem N, Blouin-Bougie J, Amara N, Landry R, Simard J (2014) Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians’ practices in primary care settings. Public Health Genom 17(4):209–220
30.
Jbilou J, Amara N, Landry R, Simard J (2011) Improving quality of genetic counseling for familial risk for breast cancer: a systematic review of the literature. In: 12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics, American Society of Human Genetics, Montreal, Canada
31.
Holsapple CW, Singh M (2001) The knowledge chain model: activities for competitiveness. Expert Syst Appl 20:77–98CrossRef
32.
Landry R, Amara N (2012) Elucidation and enhancement of knowledge and technology transfer business models. VINE J Inf Knowl Manag Syst 42:94–116
33.
Landry R, Amara N, Pablos-Mendes A, Shademani R, Gold I (2006) Knowledge translation-conceptual framework and approaches. Bull World Health Organ 84:597–602PubMedPubMedCentralCrossRef
34.
35.
Lundquist G (2003) A rich vision of technology transfer: technology value management. J Technol Transf 28:265–284CrossRef
36.
Phan PH, Siegel DS (2006) The effectiveness of university technology transfer: lessons learned from quantitative and qualitative research in the U.S. and the U.K. rensselaer working papers in economics
37.
Acton RT, Burst NM, Casebeer L, Ferguson SM, Greene P, Laird BL, Leviton L (2000) Knowledge, attitudes, and behaviors of alabama’s primary care physicians regarding cancer genetics. Acad Med 75:850–852PubMedCrossRef
38.
Fry A, Campbell H, Gudmunsdottir H, Rush R, Porteous M, Gorman D, Cull A (1999) Gps’ views on their role in cancer genetics services and current practice. Fam Pract 16:468–474PubMedCrossRef
39.
Gramling R, Nash J, Siren K, Eaton C, Culpepper L (2004) Family physician self-efficacy with screening for inherited cancer risk. AnnFamily Med 2:130–132CrossRef
40.
Gray RE, Chart P, Carroll JC, Fitch MI, Cloutier-Fisher D (1999) Family physicians’ perspectives on ovarian cancer. Cancer Prev Control 3:61–67PubMed
41.
Hampel H, Grubs RE, Walton CS, Nguyen E, Breidenbach DH, Nettles S, Callana N, Corliss M, Fox S, Hiraki S, Ku L, Neufeld-Kaiser W, Riley B, Taylor J, Weik L (2009) Genetic counseling practice analysis. J Genet Couns 18:205–216PubMedCrossRef
42.
Lobb E, Butow P, Meiser B, Tucker K, Barratt A (2001) How do geneticists and genetic counselors counsel women from high-risk breast cancer families? J Genet Couns 10:185–199CrossRef
43.
Geller G, Bernhardt BA, Doksum T, Helzlsouer KJ, Wilcox P, Holtzman NA (1998) Decision-making about breast cancer susceptibility testing: How similar are the attitudes of physicians, nurse practitioners, and at-risk women? J Clin Oncol 16:2868–2876PubMed
44.
Dunn AS, Shridharani KV, Lou W, Bernstein J, Horowizt CR (2001) Physician-patient discussions of controversial cancer screening tests. Am J Prev Med 20:130–134PubMedCrossRef
45.
Hodgson JM, Gillam LH, Sahhar MA, Metcalfe SA (2010) Testing times, challenging choices: An australian study of prenatal genetic counseling. J Genet Couns 19:22–37PubMedCrossRef
46.
Kalet A, Roberts JC, Fletcher R (1994) How do physicians talk with their patients about risks? J Gen Intern Med 9:402–404PubMedCrossRef
47.
Armstrong D, Michie S, Marteau T (1998) Revealed identity: a study of the process of genetic counselling. Soc Sci Med 47:1653–1658PubMedCrossRef
48.
Wood F, Prior L, Gray J (2003) Translations of risk: decision making in a cancer genetics service. Health Risk Soc 5:185–198CrossRef
49.
Gramling R, Clarke J, Simmons E (2009) Racial distribution of patient population and family physician endorsed importance of screening patients for inherited predisposition to cancer. J Health Care Poor Underserved 20:50–54PubMedCrossRef
50.
Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97:715–723PubMedCrossRef
51.
Henneman L, Marteau M, Timmermans RMD (2008) Clinical geneticists’ and genetic counselors’ views on the communication of genetic risks: a qualitative study. Patient Educ Couns 73:42–49PubMedCrossRef
52.
Edwards A, Elwyn G, Gwyn R (1999) General practice registrar responses to the use of different risk communication tools in simulated consultations: a focus group study. Br Med J 319:749–752CrossRef
53.
Visschers VHM, Meertens RM, Passchier WWF, de Vries NNK (2009) Probability information in risk communication: a review of the research literature. Risk Anal 29:267–287PubMedCrossRef
54.
Masny A, Daly M, Ross E, Balshem A, Gillespie D, Weil S (2003) A training course for oncology nurses in familial cancer risk assessment: evaluation of knowledge and practice. J Cancer Educ 18:20–25PubMedCrossRef
55.
56.
Mehnert A, Bergelt C, Koch U (2003) Knowledge and attitudes of gynecologists regarding genetic counseling for hereditary breast and ovarian cancer. Patient Educ Couns 49:183–188PubMedCrossRef
57.
Stockler M, Butow PN, Tattersall MHN (1993) The take-home message: doctors’ views on letters and tapes after a cancer consultation. Ann Oncol 4:549–552PubMed
58.
59.
Gutmanis I, Beynon C, Tutty L, Wathen CN, MacMillan H (2007) Factors influencing identification of and response to intimate partner violence: a survey of physicians and nurses. BMC Public Health 7:12PubMedPubMedCentralCrossRef
60.
Del Giudice ME, Grunfeld E, Harvey BJ, Piliotis E, Verma S (2009) Primary care physicians’ views of routine follow-up care of cancer survivors. J Clin Oncol 27:3338–3345PubMedCrossRef
61.
Pojskic N, MacKeigan L, Boon H, Ellison P, Breslin C (2011) Ontario family physician readiness to collaborate with community pharmacists on drug therapy management. Res Social Adm Pharm RSAP 7:39–50PubMedCrossRef
62.
Mathews M, Edwards AC, Rourke JT (2008) Retention of provisionally licensed international medical graduates: a historical cohort study of general and family physicians in newfoundland and labrador. Open Med 2:e62–e69PubMedPubMedCentralCrossRef
63.
Perry JJ, Mansour M, Sharma M, Symington C, Brehaut J, Taljaard M, Stiell IG (2010) National survey of canadian neurologists’ current practice for transient ischemic attack and the need for a clinical decision rule. Stroke 41:987–991PubMedCrossRef
64.
McCahon D, Holder R, Metcalfe A, Clifford S, Gill P, Cole T, Sleightholme HV, Wilson S (2009) General practitioners’ attitudes to assessment of genetic risk of common disorders in routine primary care. Clin Genet 76:544–551PubMedCrossRef
65.
White DB, Bonham VL, Jenkins J, Stevens N, McBride CM (2008) Too many referrals of low-risk women for brca1/2 genetic services by family physicians. Cancer Epidemiol Biomark Prev 17:2980–2986CrossRef
66.
Klabunde CN, Willis GB, McLeod CC, Dillman DA, Johnson TP, Greene SM, Brown ML (2012) Improving the quality of surveys of physicians and medical groups a research agenda. Eval Health Prof 35:477–506PubMedCrossRef
67.
McLeod CC, Klabunde CN, Willis GB, Stark D (2013) Health care provider surveys in the United States, 2000–2010 a review. Eval Health Prof 36:106–126PubMedCrossRef
68.
Ahire SL, Devaray S (2001) An empirical comparison of statistical construct validation approaches. IEEE Trans Eng Manage 48:319–329CrossRef
69.
Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T (2006) Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 24:848–855PubMedCrossRef
70.
De Bock GH, Bonnema J, Zwaan RE, Van De Velde CJH, Kievit J, Stiggelbout AM (2004) Patient’s needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 90:1144–1150PubMedPubMedCentralCrossRef
71.
Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13:735–741PubMedPubMedCentralCrossRef
72.
Bellcross C (2009) Approaches to applying breast cancer risk prediction models in clinical practice. Community Oncol 6:373–382CrossRef
73.
Amir E, Freedman OC, Seruga B, Evans DG (2010) Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 102:680–691PubMedCrossRef
74.
Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL (2003) Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21:593–601PubMedCrossRef
75.
Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT (2009) Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 11:783–789PubMedCrossRef
76.
Metcalfe KA, Kim-Sing C, Ghadirian P, Sun P, Narod SA (2014) Health care provider recommendations for reducing cancer risks among women with a brca1 or brca2 mutation. Clin Genet 85:21–30PubMedCrossRef
77.
Warner E, Heisey R, Carroll JC (2012) Primer: applying the 2011 canadian guidelines for breast cancer screening in practice. Can Med Assoc J 184:1803–1807CrossRef
78.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in brca1 and brca2 mutation carriers: the prose study group. J Clin Oncol 22:1055–1062PubMedCrossRef
79.
McQuirter M, Castiglia LL, Loiselle CG, Wong N (2010) Decision-making process of women carrying a brca1 or brca2 mutation who have chosen prophylactic mastectomy. Oncol Nurs Forum 37:313–320PubMedCrossRef
80.
Kim-Sing C, Weir L, Kuusk U (2004) Breast cancer risk management for moderate-risk and high-risk women. Women 50:10
Metadata
Title
The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes
Authors
Nabil Amara
Jolyane Blouin-Bougie
Jalila Jbilou
Norrin Halilem
Jacques Simard
Réjean Landry
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9835-7

Other articles of this Issue 1/2016

Familial Cancer 1/2016 Go to the issue

Original Article

Association between the FTOrs8050136 polymorphism and cancer risk: a meta-analysis

Original Article

Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients

Original Article

Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry

Short Communication

First report of somatic mosaicism for mutations in STK11 in four patients with Peutz–Jeghers syndrome

Short Communication

Aortopulmonary window parathyroid gland causing primary hyperparathyroidism in men type 1 syndrome

Original Article

Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits